This trade activity should not be overlooked: Nuvation Bio Inc (NUVB)

With 2.37 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.14 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.7800 whereas the lowest price it dropped to was $3.4050. The 52-week range on NUVB shows that it touched its highest point at $4.16 and its lowest point at $0.95 during that stretch. It currently has a 1-year price target of $6.40. Beta for the stock currently stands at 1.37.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NUVB was up-trending over the past week, with a rise of 59.74%, but this was up by 97.33% over a month. Three-month performance surged to 141.18% while six-month performance rose 165.47%. The stock gained 122.29% in the past year, while it has gained 144.37% so far this year. A look at the trailing 12-month EPS for NUVB yields -0.35 with Next year EPS estimates of -0.53. For the next quarter, that number is -0.09. This implies an EPS growth rate of -3.33% for this year and -45.16% for next year.

Float and Shares Shorts:

At present, 218.05 million NUVB shares are outstanding with a float of 143.13 million shares on hand for trading. On Mar 15, 2024, short shares totaled 2.82 million, which was 1.29% higher than short shares on Feb 15, 2024. In addition to NUVL as the firm’s Nuvalent, Inc., NUVB serves as its Nuvation Bio Inc.

Institutional Ownership:

Through their ownership of 62.01% of NUVB’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NUVB since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.